A243 Morphologic and Functional Analysis of CD4+ T Cells in Chronic Graft-versus-Host Disease (cGVHD): a Comparison of Photopheresis (PXP) and PLEX as Treatment Options

A195 Foreign Antigen Rejection of Donor Cells: A Novel Approach to Enhance Graft-versus-Host Disease (GvHD) Protection in a Rat Model

A244 Impact of Stem Cell Source on Long-term Survival and Progression of Chronic Graft-versus-Host Disease (cGVHD)

A185 Hematopoietic Progenitor Cell Infusion in High-Risk MDS and AML Patients Aged Over 50 Years: Feasibility and Outcome

A246 Expression of the CD235a Antigen in a Subset of Chronic Graft-versus-Host Disease-Related Cutaneous Lesions

A180 Impact of HLA Antigen Mismatch on Chronic Graft-versus-Host Disease (cGVHD) and Survival in Hematopoietic Stem Cell Transplant Recipients

A247 Role of Malignant Chromosome Aberrations in Myelodysplastic Syndrome of Donor Cells

A121 Outcome of Umbilical Cord Blood Transplantation in Adult Patients with Chronic Active Epstein-Barr Virus Infection

A176 Early withdrawal of immunosuppressive therapy in haploidentical bone marrow transplantation with posttransplantation cyclophosphamide increases chronic GvHD and can reduce relapses.

A181 Lower incidence of GvHD after cord blood transplantation for hematological malignancies in comparison with haploidentical stem cell transplantation from other donors: 20-years experience in a single institute

A182 Outcome of umbilical cord blood transplantation in adult patients with chronic active Epstein-Barr virus infection

A181 Lower incidence of GvHD after cord blood transplantation for hematological malignancies in comparison with haploidentical stem cell transplantation from other donors: 20-years experience in a single institute
Platelet transfusion refractoriness after T-cell replete haploidentical transplantation is associated with inferior clinical outcomes

Pre-treatment evaluation of liver dysfunction including elastography in patients receiving allogeneic hematopoietic cell transplantation

Prophylactic recombinant thrombomodulin prevents hepatic veno-occlusive disease/withdrawal obstruction syndrome in high-risk pediatric patients that undergo hematopoietic stem cell transplants

Protective effect of early human cytomegalovirus reactivation on relapse of myeloproliferative disorders after allogeneic hematopoietic stem cell transplantation

Quality of life and dance – receptor landscape after HLA-matched sibling hematopoietic stem cell transplantation – methods and preliminary results

B066 Software-based image analysis of CT scans in patients after allogeneic stem cell transplantation for pulmonary chronic "graft-versus-host" disease diagnosis

The choice of effectiveness criteria effects combinations of economic evaluation of newer allogeneic bone marrow transplantation modalities: example based on a randomised multicenter trial comparing two Reduced Intensity conditioning regimens (FLU-BU-ATG) vs. (FLU-TBI) for matched related Allo-SCT.
Sequential Fludarabine, Ara-C, Etoside (PLAV) followed by Fludarabine/Busulfan reduced toxicity conditioning is safe and effective salvage for adult patients with refractory acute myeloid leukemia and high risk myelodysplasia.

SeQUENCIAL HIGH-DOSE CHEMOTHERAPY REINDUCTION FOLLOWED BY HALOIDENITAL TRANSPLANTATION IN ACUTE LEUKEMIAS.

Stem Cell Transplantation (SCT) in Pediatric Intermediate Risk Acute Myeloid Leukemia (AML) — Reporting 8 years of data from a CIMBRAT Member-Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Sustained molecular remission in an elderly patient with RCSD1-AML positive acute lymphoblastic leukemia enabled by dasatinib and allogeneic stem cell transplantation.

Sustained remission with Sorafenib treatment for extramedullary FELT-AML relapse after allogeneic stem cell transplantation.

TCRD(p)/CD20 depletion in hematopoietic stem cells transplantation from matched unrelated and haploidentical donors following treosulfan or TBI-based conditioning in pediatric acute lymphoblastic leukemia patients.

The efficacy and toxicity of busulphanorma in patients with relapsed/refractory acute myeloid leukaemia: Russian multicenter experience.

The mechanism of sorafenib anti-leukaemic effect seen in AML patients relapsing post alloHSCT involves the augmentation of alloreactivity which includes infiltration of the affected marrow by CD8+ cells having PD-1 receptor which allows increased lymphocytes with anti-tumour potential.

The outcome of older patients with acute myeloid leukemia or high risk myelodysplastic syndrome treated with allogeneic hematopoietic stem cell transplantation.

Transplant program evolution within 30 years and acute leukemia improved outcome.

Treatment of Refractory Pediatric Acute Lymphoblastic T Cell Leukaemia with Anti-Programmed Cell Death Protein 1 (PD-1) Antibody after Allogeneic Stem Cell Transplantation.

Unmanipulated haploidentical related donor HCT: a single center experience.

A feasible way to control infection by hematopoietic stem cell transplantation for children with apraxic anemia and refractory active infections.

Allogeneic aplastic anemia in the context of hematopoietic paroxysmal nocturnal hemoglobinuria: intensive immunosuppression and esculafumab treatment. A retrospective analysis from two reference centers.

Bone marrow transplantation for children with acquired bone marrow failure.

Decreased toxicity of allogeneic matched related donor bone marrow transplantation for pediatric patients with severe aplastic anemia using "low dose" cyclophosphamide, ATG plus fludarabine. A pilot study and novel assessment of a new care.

LONG TERM OUTCOME OF PATIENTS WITH SEVERE APLASTIC ANEMIA RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING NONMYELOABLATIVE CONDITIONING WITH FLUDARABINE AND LOW DOSE TOTAL BODY IRRADIATION

PAROXYMAL NOCTURNAL HEMOGLOBINURIA: A LONG TERM SINGLE CENTER EXPERIENCE.

TRANSPLANTATION IN PATIENTS WITH ACQUIRED APLASTIC ANEMIA OVER THE AGE OF 40: MORTALITY HAS NOT BEEN REDUCED IN 2010-2015.

Aplastic hematopoietic stem cell transplantation as curative therapy for early-onset, refractory Cohn’s disease.

Autologous hematopoietic stem cell transplantation (ASCT) for Cohn’s disease (CD): a retrospective study of outcomes from the EBMT Autoimmune Diseases Working Party (ADAP).

CRk Myelofibrosis Stem T-cells: novel players in Rheumatoid Arthritis.

EBV and CMV reactivation following autologous hematopoietic stem cell transplantation (HSCT) for autoimmune neurological diseases resolves spontaneously and rarely requires treatment.

Exacerbation of Multiple Sclerosis Symptoms in Patients Undergoing Autologous Stem Cell Transplantation.

Inflammatory immune response after autologous transplantation in neurologic diseases.

Long-term outcomes and late effects at children with multiple sclerosis and neuromyelitis optica after hematopoietic stem cell transplantation.

Busulfan/Fludarabine versus thiopeta/Fludarabine as a reduced-intensity preparative regimen for allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis: a phase II, multicentre, randomised trial.

Impact of liver stiffness measured by transient liver elastography (FibroScan) on liver toxicity in myelofibrosis patients undergoing allogeneic stem cell transplantation.

Impact of pre-transplant rasburicase in myelofibrosis patients on outcome after allogeneic stem cell transplantation.


Long-term outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic lymphocytic Leukemia (CLL): 10 year follow-up of the GCLL/CLLX trial.

No evidence for an increased GvHD risk associated with post-transplant Tdelisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT Chronic Lymphoma and Lymphoma Working Parties.

Outcomes of Patients with Advanced CML: Treated with Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Tyrosine Kinase Inhibitors (TKIs).

Reduced-intensity conditioning with allogeneic stem cell transplantation in 23 patients with high-risk chronic lymphocytic leukemia: single centre experience.

Role of allo-HCT in the treatment of patients with TS102 mutation in the TKI era.

Splenomegaly, high DPSII plus score, rasburicase and chronic GVHD independently influence survival after myeloablative allo-HCT in patients with primary myelofibrosis.

The role of allo-HCT and autologous hematopoietic transplantation in posttransplant cyclophosphamide for patients with beta-thalassemia major.

Use of First or Second Generation TCR for CML after Allogeneic Hematopoietic Cell Transplantation: A Study by the CIBMTR of the EBMT.

A treosulan based protocol for thalassemia major -- graft kinetics in different age groups.

Allogeneic Hematopoietic Stem Cell Transplantation in Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Retrospective Study of the Chronic Infections and Inborn Errors Working Parties (CIBMTR and EEWB) of the EBMT.

Allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide for patients with inherited non-malignant diseases.

An exploratory, open-label study to evaluate the safety and feasibility of ATX-381, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host autoreactive T-cells (using photodynamic treatment), as adjunctive treatment to a T-cell depleted haploidentical hematopoietic stem cell transplantation in patients with beta-thalassemia major.

Changing the Shape of Sickle Cell Disease Treatment: A Hemerological Study of a Case that Changed a Family and a Medical Practice.

Delftloft (DF) prophylaxis and adjustment of basiliximab schedule to prevent xeno-occlusive disease and thrombotic microangiopathy in an infant with a Membrane Cofactor Protein (MCP) gene mutation and Metachromatic Leukodystrophy undergoing Hematopoietic Stem Cell Gene Therapy (HSCT).

Disease-specific conditioning regimen in hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes.

Haploidentical hematopoietic bone marrow transplantation with consecutive living kidney transplantation from the donor in a sickle cell disease patient with end-stage renal failure.

Haploidentical transplantation with post-transplant cyclophosphamide for pediatric non-malignant disorders.

Hematopoietic Stem Cell Transplant for Sickle Cell Disease: The Indian Experience.

Hematopoietic stem cell transplantation for children with thalassemia: a start up cooperative project in iraq Kirkutan.

Long Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Thalassemia Major.

Long-time follow-up and late effects estimation in patients with Hurler syndrome after allogenic hematopoietic stem cell transplantation: results of Russian joint study.

Non-PET1-receptor positive T-cell Progenitor Cells Transplantation: A Case Series.

Non-myeloablative alectumumab/low dose total body irradiation conditioning for children undergoing HLA-matched sibling donor hematopoietic cell transplantation for sickle cell disease.

Successful allogeneic hematopoietic stem cells transplantation from HLA-identical sibling selected with preimplantation genetic diagnosis (PGD) with HLA matching in a patient with Shwachman-Diamond syndrome (SDS).

The safety and efficacy of filipread Haploidentical (HII) stem cell transplantation utilizing CD34 enrichment and CD34 addback in patients with high risk sickle cell disease (SDS) (IND 143599).

A Clinical Prognostic Index for Assessing Patients aged >60 Being Considered for High-Dose Therapy and Autologous Stem-Cell Transplantation in Refractory or Relapsing High-Grade Non-Hodgkin Lymphoma.

Allogeneic Stem Cell Transplantation (auto-SCT) after Treosulan-based conditioning regimen for B-cell Non-Hodgkin Lymphoma (B-NHL).

Autologous Stem Cell Transplantation for Systemic Anaplastic Large Cell Lymphoma: A Retrospective Analysis of the Lymphoma Working Party (LWP) of the EBMT.

Autologous Stem Cell Transplantation in Refractory Connective Tissue Disease Type II – The Irish Experience.

Autologous stem cell transplantation in refractory or relapsed Hodgkin lymphoma.

Bendamustine : Promising activity in post-brentuximab failure Hodgkin’s lymphoma patients who had also failed a prior autologous HCT and possible successful bridging to autologous HCT.

Breustubam-vedotin for relapsed or refractory Hodgkin Lymphoma, Single center experience King Faisal Specialist Hosp. & Research Centre Riyadh, Kingdom of Saudi Arabia.

Effect of infection on transplant outcomes after autologous peripheral blood stem cell transplantation: a retrospective study of Japanese registry data.

Efficacy and toxicity of BEAC versus BEAM high-dose chemotherapy in patients with mantle cell lymphoma undergoing autograft stem cell transplantation.

Efficacy of Allogeneic Hematopoietic Cell Transplantation in peripheral T-cell lymphomas in the front-line and relapsed/refractory setting: Results of a systematic Review/Meta-analysis.

High-dose methotrexate and autologous peripheral blood stem cell transplantation as a salvage therapy for diffusely large B-cell lymphoma refractory to 2nd or 3rd line treatment.

High-Dose Methotrexate and Autologous Progenitor Cells Transplantation as a Salvage Therapy for Relapsed or Refractory Hodgkin Lymphoma: A follow up analysis of King Hussain Center Case Results and Prognostic Variables.

HIV RELATED HEMATOLOGICAL MALIGANCE: A SINGLE CENTER EXPERIENCE.

Long term survival of refractory Hodgkin lymphoma after high dose chemotherapy (HDc) and autologous stem cell transplant (ASCT): Single institution analysis of 177 patients.

Long-term outcome of reduced intensity conditioning allogeneic stem cell transplantation in advanced stage mycosis fungoides and Sezary syndrome.

Outcomes of allogeneic hematopoietic stem cell transplantation for patients with hematological malignancies: a retrospective-multicenter experience.

Outcomes of both high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation and conventional chemotherapy alone for mantle cell lymphoma: A 12-year single-center experience.

Outcomes of hematopoietic stem cell transplantation for extramedullary natural killer/T-cell lymphoma, nasal type: a study from the Societe Franchise du Greffe de Moelle et de Therapie Cellulaire.

Phase I study of myeloablative conditioning regimen of full-dose busulfan, melphalan, and fludarabine for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed aggressive lymphoma.

Primary Cutaneous T-Cell Lymphoma (CTCL): long-term follow-up after allogeneic hematopoietic stem cell transplant (HSCT).

Results of Frontline High Dose Chemotherapy in High-Risk DLBCL Patients Stratified According to The NCCN-IPI.